Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
← catalyst calendarNCT07566195 · readout in 863 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Clinact, Multihealth Group, Contract Research Organization.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
59estimated
Sites
13
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-05 | actual | When the study began enrolling |
| Primary completion | 2028-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Obstructive Pulmonary Disease
- COPD
Interventions
- Drug: Tozorakimab Dose Regimen 1
- Drug: Tozorakimab Dose Regimen 2
Primary outcome
what the primary-completion date above is the date OFAdverse events
measured 2-3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed